Tai'ai (telitacicept) / Rongchang Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   1 News 


12345»
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Review, Journal:  The Latest Progress in the Application of Telitacicept in Autoimmune Diseases. (Pubmed Central) -  Dec 12, 2024   
    So far, the efficacy and safety of telitacicept in autoimmune diseases have been fully demonstrated in clinical practice. There are still many unresolved issues regarding the timing of initiation and discontinuation, still needs to be evaluated in future studies.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma, Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Review, Journal:  Neuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review. (Pubmed Central) -  Nov 19, 2024   
    Simultaneously, sequential disease-modifying therapy was initiated, starting with long-term oral administration of mycophenolate mofetil, followed by cyclophosphamide, telitacicept, and Inebilizumab...Early and comprehensive evaluation of autoimmune diseases is crucial in patients with NMOSD presenting with u-LETM as the initial symptom. Prompt treatment initiation, followed by disease-modifying therapy, is essential for improving patient prognosis.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) (clinicaltrials.gov) -  Nov 18, 2024   
    P3,  N=350, Active, not recruiting, 
    Prompt treatment initiation, followed by disease-modifying therapy, is essential for improving patient prognosis. Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Mar 2027 | Trial primary completion date: Jun 2025 --> Jan 2027
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    New P4 trial, Immune cell:  Immune Cell Subsets in SLE Patients Treated with Telitacicept (clinicaltrials.gov) -  Nov 7, 2024   
    P4,  N=50, Active, not recruiting, 
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    New trial:  Efficacy and Safety of Telitacicept in IgAN (clinicaltrials.gov) -  Oct 23, 2024   
    P=N/A,  N=118, Not yet recruiting, 
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion date, Trial primary completion date, Real-world evidence, Compliance, Real-world:  Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) -  Oct 1, 2024   
    P=N/A,  N=139, Recruiting, 
    After a 24-week follow-up, the incidence of adverse events was lower for telitacicept than for conventional IS therapy. Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
  • ||||||||||  Fabhalta (iptacopan) / Novartis, Tai'ai (telitacicept) / Rongchang Pharma, atacicept (VT-001) / Vera Therap
    Comparative Efficacy and Safety of New Therapies for IgA Nephropathy: A Systematic Review and Network Meta-Analysis (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3160;    
    Recruiting --> Active, not recruiting This systematic review and network meta-analysis indicate Mycophenolate and Telitacicept are most effective in reducing UPCR and improving eGFR, suggesting these as preferable treatments for IgAN patients.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion date, Trial primary completion date:  A Study of Telitacicept in Lupus Nephritis (clinicaltrials.gov) -  Sep 22, 2024   
    P2,  N=120, Recruiting, 
    Participant recruitment and exclusion flowchart. Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion date, Trial primary completion date:  A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus (clinicaltrials.gov) -  Sep 22, 2024   
    P1,  N=12, Recruiting, 
    Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Dec 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Sep 2025
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Review, Journal:  Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases. (Pubmed Central) -  Sep 9, 2024   
    This review consolidates information on the mechanistic actions, dosing regimens, pharmacokinetics, efficacy, and safety profile of telitacicept-a dual-targeted biological agent. It integrates findings from prior experiments and pharmacokinetic analyses in the treatment of RA and SLE, striving to offer a comprehensive overview of telitacicept's research advancements.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment open, Trial completion date, Trial primary completion date:  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG) (clinicaltrials.gov) -  Aug 19, 2024   
    P3,  N=180, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Oct 2027 | Trial primary completion date: Apr 2026 --> Jul 2026
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Journal:  Efficacy and safety of telitacicept in patients with lupus nephritis. (Pubmed Central) -  Aug 2, 2024   
    Furthermore, it reduced the dose of glucocorticoid and immunosuppressive medicines. Therefore, telitacicept may be a promising treatment option for individuals with lupus nephritis.
  • ||||||||||  Filspari (sparsentan) / Travere Therap, Tai'ai (telitacicept) / Rongchang Pharma, Tarpeyo (budesonide) / Calliditas, Stada
    Review, Journal:  Current understanding and new insights in the treatment of IgA nephropathy. (Pubmed Central) -  Jul 3, 2024   
    Finally, the recent large randomized controlled trials focusing on these novel targets have been summarized, among which Nefecon and Sparsentan have received approval and Telitacicept have been used off-label for IgAN. In the future, emerging treatment approaches for IgAN is likely to evolve, which will signify a shift in the management of the IgAN from traditional immunosuppressive approaches to an era of targeted treatment based on the understanding of the pathogenic mechanisms.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment open:  Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients (clinicaltrials.gov) -  Jul 3, 2024   
    P=N/A,  N=176, Recruiting, 
    In the future, emerging treatment approaches for IgAN is likely to evolve, which will signify a shift in the management of the IgAN from traditional immunosuppressive approaches to an era of targeted treatment based on the understanding of the pathogenic mechanisms. Not yet recruiting --> Recruiting